异动解读 | 三生制药盘中大涨5.27%,辉瑞加速SSGJ-707全球开发计划

异动解读
Jul 28

三生制药(01530.HK)今日盘中大涨5.27%,引发市场关注。截至午后13:38,该股报价29.95港元。

消息面上,三生制药近日公布与辉瑞就PD-1/VEGF双特异性抗体SSGJ-707达成的全球授权协议已于7月24日正式生效。根据协议,三生制药将获得12.5亿美元首付款、最高48亿美元里程碑付款及双位数分级销售分成。此外,辉瑞还将以每股25.2港元认购三生制药约7.85亿港元股份。

市场分析人士认为,辉瑞计划加速SSGJ-707在全球的III期临床试验,评估其单药及联合疗法的潜力,这将有助于加快该药物的开发进程。SSGJ-707在此前公布的临床数据中展现出良好的疗效,在34例患者中实现64.7%的客观缓解率。多家券商看好SSGJ-707的市场前景,纷纷上调三生制药的目标价,其中招银国际将目标价上调33%至37.67港元,维持"买入"评级。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10